ClinicalTrials.gg
CompletedNCT03091595Updated May 3, 2023

E4/DRSP Ovarian Function Inhibition Study

A Phase 2 interventional study of 15 mg E4/3 mg DRSP and 20 mcg EE/3 mg DRSP in Prevention of Pregnancy, sponsored by Estetra. Completed at 1 site in Netherlands. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Estetra · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

A combined oral contraceptive (COC) containing 15 mg E4 and 3 mg DRSP administered for 24 days followed by 4 placebo tablets, is being evaluated for further development. This study will investigate the effect of this COC on ovarian function inhibition, levels of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2) and progesterone during 3 treatment cycles in comparison with the reference COC 20 mcg EE/3 mg DRSP.

02

Conditions studied

  • Prevention of Pregnancy
03

In context

Lead sponsor

Estetra is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy female subjects, as determined by medical history, physical examination including breast examination, gynecological examination (including cervical smear [Pap smear]), vital signs, , echocardiogram, and laboratory tests.
  • Negative pregnancy test at subject screening.
  • Women who ovulate in the Pre-Treatment Cycle.
  • Willing to use a non-hormonal method of (e.g. condom) during the , Pre-Treatment Cycle and Post-Treatment Cycle.
  • between 18.0 and 35.0 kg/m², inclusive, at time of Screening.
  • Able to fulfill the requirements of the protocol and have indicated a willingness to participate in the study by providing written form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Irregular menstrual cycle.
  • Amenorrhea or abnormal uterine bleeding.
  • abnormal laboratory result at Screening.
  • Clinically significant abnormalities of the uterus and/or ovaries detected by examination and/or ultrasound.
  • Known to any of the or reference product ingredients.
  • Intention to become pregnant during the course of the study.
  • Pregnancy during accurate hormonal use in the past.
  • Dyslipoproteinemia requiring active treatment with antilipidemic agent.
  • Diabetes mellitus with vascular involvement (nephropathy, retinopathy, neuropathy, other) or diabetes mellitus of more than 20-year duration.
  • Any arterial hypertension.
  • Any condition associated with an increased risk of venous thromboembolism and/or arterial thromboembolism.
  • Complicated valvular heart disease.
  • History of pregnancy-related cardiomyopathy or moderately or severely impaired cardiac function.
  • Systemic lupus erythematosus.
  • Presence or history of migraine with aura.
  • Abnormal Papanicolaou (PAP) smear result.
  • Presence of an undiagnosed breast mass.
  • Current symptomatic gallbladder disease.
  • History of COC-related cholestasis.
  • Presence or history of severe hepatic disease.
  • Presence or history of pancreatitis if associated with hypertriglyceridemia.
  • Porphyria.
  • Presence or history of hepatocellular adenoma or malignant liver tumors.
  • Renal impairment.
  • Hyperkaliemia or presence of conditions that predispose to hyperkaliemia.
  • Presence or history of hormone-related .
  • History of non-hormone-related malignancy within 5 years before Screening. Subjects with a non-melanoma skin cancer are allowed in the study.
  • Use of drugs potentially triggering interactions with COCs.
  • History of alcohol or drug abuse.
  • Any prior procedure, disease or condition that could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the investigational product.
  • Uncontrolled thyroid disorders.
  • Have received an investigational drug within the last 2 cycles prior to start of Pre-Treatment Cycle. Subjects who participated in an oral contraceptive clinical study, using Food and Drug Administration (FDA)/European Union (EU) approved active ingredients, may start the Pre-Treatment Cycle one cycle after last medication intake of the preceding study.
  • Sponsor, contract research organization (CRO) or PI's site personnel directly affiliated with this study.
  • Is judged by the PI to be unsuitable for any reason.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    15 mg E4/3 mg DRSP

    15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.

    Drug: 15 mg E4/3 mg DRSP

  • Active comparator
    20 mcg EE/3 mg DRSP

    20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.

    Drug: 20 mcg EE/3 mg DRSP

Interventions

  • Drug15 mg E4/3 mg DRSP

    Drug pages: Estetrol · Drospirenone

    15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles

    Also known as: 15 mg estetrol combined with 3 mg drospirenone

  • Drug20 mcg EE/3 mg DRSP

    20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles

    Also known as: 20 mcg ethinylestradiol combined with 3 mg drospirenone (Yaz)

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with ovarian inhibition at treatment Cycle 1

    Ovarian inhibition will be assessed by rating the suppression of ovaries using the Hoogland score. This score is based on: * the follicular size assessed by transvaginal ultrasound (TVUS) * endogenous hormone levels: serum E2, and serum progesterone.

    Time frame: All assessments will be performed once every 3 days starting treatment Cycle 1 Day 3 (± 1 day) until Day 27 (± 1 day) (one treatment cycle = 28 days).

  2. Proportion of subjects with ovarian inhibition at treatment Cycle 3

    Ovarian inhibition will be assessed by rating the suppression of ovaries using the Hoogland score. This score is based on: * the follicular size assessed by TVUS * endogenous hormone levels: serum E2, and serum progesterone.

    Time frame: All assessments will be performed once every 3 days starting treatment Cycle 3 Day 3 (± 1 day) until Day 27 (± 1 day) (one treatment cycle = 28 days).

Secondary outcomes

  1. Serum level of luteinizing hormone (LH)

    Blood samples will be taken at regular time points defined in the time frame.

    Time frame: On cycle Day 3, 6, 9, 12, 15, 18, 21, 24, 27 at treatment Cycle 1 and treatment Cycle 3 and on cycle Day 3 of the Treatment Cycle 2 (each treatment cycle = 28 days)

  2. Serum level of follicle stimulating hormone (FSH)

    Blood samples will be taken at regular time points defined in the time frame.

    Time frame: On cycle Day 3, 6, 9, 12, 15, 18, 21, 24, 27 at treatment Cycle 1 and treatment Cycle 3 and on cycle Day 3 of the Treatment Cycle 2 (each treatment cycle = 28 days)

  3. Serum level of estradiol (E2)

    Blood samples will be taken at regular time points defined in the time frame.

    Time frame: On cycle Day 3, 6, 9, 12, 15, 18, 21, 24, 27 at treatment Cycle 1 and treatment Cycle 3 and on cycle Day 3 of the Treatment Cycle 2 (each treatment cycle = 28 days)

  4. Serum level of progesterone (P)

    Blood samples will be taken at regular time points defined in the time frame.

    Time frame: On cycle Day 3, 6, 9, 12, 15, 18, 21, 24, 27 at treatment Cycle 1 and treatment Cycle 3 and on cycle Day 3 of the Treatment Cycle 2 (each treatment cycle = 28 days)

  5. Maximum endometrial thickness

    Endometrial thickness will be measured using transvaginal ultrasound (TVUS). Maximum endometrial thickness was defined as the largest endometrial thickness during a cycle.

    Time frame: From Baseline (study day 1), through 3 treatment cycles and up to Cycle Day 36 (±1) of the Post-Treatment Cycle (study day 120 (±1)) (each treatment cycle = 28 days)

  6. Mean diameter of the largest follicle

    Follicular size will be measured using TVUS.

    Time frame: Day 3 to Day 24 of Post-Treatment Cycle

  7. Number of participants who experience at least one Treatment-Emergent Adverse Event (TEAE)

    Time frame: Day 1 to Follow-Up Visit (+ 30 days)

  8. Number of participants who experience pregnancy during treatment

    Time frame: Cycle 1 Day 1 to Follow-Up Visit (+ 30 days) (each treatment cycle = 28 days)

  9. Number of participants who experience a clinically significant change in physical examination results

    Time frame: Day 1 to End of Follow-Up Visit (+ 30 Days)

  10. Number of participants who experience a clinically significant change in gynecological examination results

    Time frame: Day 1 to End of Follow-Up Visit (+ 30 Days)

  11. Number of participants who experience a clinically significant change in clinical laboratory results

    Time frame: Day 1 to End of Follow-Up Visit (+ 30 Days)

  12. Number of participants who experience a clinically significant change in electrocardiogram (ECG) results

    Time frame: Day 1 to End of Cycle 3 (Day 28) (each treatment cycle = 28 days)

  13. Number of participants who experience a clinically significant change in echocardiogram results

    Time frame: Day 1 to End of Cycle 3 (Day 28) (each treatment cycle = 28 days)

  14. Change from Baseline in diastolic blood pressure

    Time frame: From Baseline (study day 1), through 3 treatment cycles and up to Cycle Day 36 (±1) of the Post-Treatment Cycle (study day 120 (±1)) (each treatment cycle = 28 days)

  15. Change from Baseline in systolic blood pressure

    Time frame: From Baseline (study day 1), through 3 treatment cycles and up to Cycle Day 36 (±1) of the Post-Treatment Cycle (study day 120 (±1)) (each treatment cycle = 28 days)

  16. Change from Baseline in pulse rate

    Time frame: From Baseline (study day 1), through 3 treatment cycles and up to Cycle Day 36 (±1) of the Post-Treatment Cycle (study day 120 (±1)) (each treatment cycle = 28 days)

07

Study locations

1 site
  • Dinox BV
    Groningen, 9713 CZ, Netherlands
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Jun 2018, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2017
First posted
Mar 27, 2017
StartActual
Feb 7, 2017
Primary completionActual
Jun 8, 2018
CompletionActual
Jun 8, 2018
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03091595
Lead sponsor
Estetra
Responsible party
Sponsor
First posted
Mar 27, 2017
Start date
Feb 7, 2017
Primary completion
Jun 8, 2018
Completion
Jun 8, 2018
Last update
May 3, 2023

Study contacts

Christine Klipping
principal investigator · Dinox BV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estetrol · Drospirenone

Start the discussion